Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Pfizer (NYSE: PFE) hit a new 52-week high Tuesday as it is currently trading at $25.19, above its previous 52-week high of $25.15 with one million shares traded as of 9:36 a.m. ET. Average volume has been 31.7 million shares over the past 30 days. Pfizer has a market cap of $185.62 billion and is part of the health care sector and drugs industry. Shares are up 14.8% year to date as of the close of trading on Monday. Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 21.1, above the average drugs industry P/E ratio of 18.4 and above the S&P 500 P/E ratio of 17.7.
ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Pfizer Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.